Suppr超能文献

[复发性生殖器疱疹的阿昔洛韦长期治疗。临床、病毒学及免疫学反应]

[Prolonged treatment with acyclovir in recurrent genital herpes. Clinical, virological, and immunological response].

作者信息

Velasco M, Saavedra T, Sepúlveda C, Suárez M

机构信息

Departamento de Medicina, Hospital Clínico, Universidad de Chile.

出版信息

Rev Med Chil. 1991 Aug;119(8):876-80.

PMID:1668960
Abstract

The effect of a prolonged course of oral acyclovir was evaluated in 55 pts with recurrent genital herpes (36 men and 19 women). The pts were voluntarily enrolled after an acute episode, with tissue culture viral isolation. All the pts received an initial course with 200 mg of acyclovir x 5 for 10 days. Then they were randomly assigned to two groups (double-blind), one received 400 mg t.d. for 6 months and the other placebo. Clinical, virological and immunological follow-up included: tissue culture viral isolation, HSV antibody detection, serum Igs levels, T and B cell count, T-cell subsets (OKT3, OKT4, OKT8), C3 and phagocytosis test. The drug was well tolerated with hardly any side effects. Recurrences diminished dramatically in acyclovir treated pts, in contrast with those receiving placebo who did not show modification in viral recurrences. The immunological study was normal in most pts and did not change significantly during the trial.

摘要

对55例复发性生殖器疱疹患者(36例男性和19例女性)评估了口服阿昔洛韦长疗程治疗的效果。患者在急性发作后经组织培养病毒分离自愿入组。所有患者接受初始疗程,口服阿昔洛韦200mg,每日5次,共10天。然后将他们随机分为两组(双盲),一组接受400mg,每日3次,共6个月,另一组接受安慰剂。临床、病毒学和免疫学随访包括:组织培养病毒分离、HSV抗体检测、血清免疫球蛋白水平、T和B细胞计数、T细胞亚群(OKT3、OKT4、OKT8)、C3和吞噬试验。该药物耐受性良好,几乎没有任何副作用。与接受安慰剂且病毒复发无变化的患者相比,阿昔洛韦治疗的患者复发显著减少。大多数患者的免疫学研究结果正常,且在试验期间无明显变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验